Mutational study of the role of N-terminal amino acid residues in tetrachlorohydroquinone reductive dehalogenase from Sphingomonas sp. UG30.

M. Habash,Byron C. H. Chu,J. Trevors,Hung Lee

DOI: https://doi.org/10.1016/j.resmic.2009.07.010

IF: 3.946

2009-10-01

Research in Microbiology

Abstract:

What problem does this paper attempt to address?

Validation of American Heart Association PREVENT Cardiovascular Disease Risk Equations

Britton Scheuermann,Alexandra Brown,Trenton Colburn,Hisham Hakeem,Chen Hoe Chow,Carl Ade

DOI: https://doi.org/10.1001/jamanetworkopen.2024.38311

2024-10-12

JAMA Network Open

Abstract:Importance The American Heart Association's Predicting Risk of Cardiovascular Disease Events (PREVENT) equations were developed to extend and improve on previous cardiovascular disease (CVD) risk assessments for the purpose of treatment initiation and patient-clinician communication. Objective To assess prognostic capabilities, calibration, and discrimination of the PREVENT equations in a study sample representative of the noninstitutionalized, US general population. Design, Setting, and Participants This prognostic study used data from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2010 data cycles. Participants included adults for whom 10-year follow-up data were available. Data curation and analyses took place from December 2023 through May 2024. Main Outcomes and Measures Primary measures were risk estimated by the PREVENT equations, as well as risk estimates from the previous Pooled Cohort Equations (PCEs). The primary outcome was composite CVD-related mortality at 10 years of follow-up. Additional analyses compared the PREVENT equations against the PCEs. Model discrimination was assessed with receiver-operator characteristic curves and Harrell C statistic from proportional hazard regression; model calibration was determined as the slope of predicted versus observed risk. Results The study cohort, accounting for NHANES complex survey design, consisted of 172.9 million participants (mean age, 45.0 years [95% CI, 44.6-45.4 years]; 52.1% women [95% CI, 51.5%-52.6%]). In analyses adjusted for the NHANES survey design, a 1% increase in PREVENT risk estimates was statistically significantly associated with increased CVD mortality risk (hazard ratio, 1.090; 95% CI, 1.087-1.094). PREVENT risk scores demonstrated excellent discrimination (C statistic, 0.890; 95% CI, 0.881-0.898) but moderate underfitting of the model (calibration slope, 1.13; 95% CI, 1.06-1.21). PREVENT risk models performed statistically significantly better than the PCEs, as assessed by the net reclassification index (0.093; 95% CI, 0.073-0.115). Conclusions and Relevance In this prognostic study of the PREVENT equations, PREVENT risk estimates demonstrated excellent discrimination and only modest discrepancies in calibration. These findings provided evidence supporting utilization of the PREVENT equations for application in the intended population as suggested by the American Heart Association.

medicine, general & internal
Validating the PREVENT Equations for Cardiovascular Risk Assessment

Sridhar Mangalesh,Michael G. Nanna

DOI: https://doi.org/10.1001/jamanetworkopen.2024.38284

2024-10-12

JAMA Network Open

Abstract:Scheuermann et al 1 set out to validate the American Heart Association's Predicting Risk of Cardiovascular Disease Events (PREVENT) 10-year cardiovascular disease risk equations, 2 using a large US-based population, and to compare these equations with the Pooled Cohort Equations (PCEs). The study focused on the base PREVENT equation and applied risk scores within competing-risks adjusted hazard regression models. The PREVENT equations demonstrated exceptional performance in predicting fatal cardiovascular events over a 10-year follow-up period, with a C statistic of 0.890. The performance was notably higher than what was previously reported by the American Heart Association working group that developed the equations. 2 The results remained consistent even after well-designed sensitivity analyses, which excluded participants with outlier values of clinical variables, adhering to the methods used by the PREVENT working group. Most importantly, the study robustly demonstrated the improved predictive capability of the PREVENT equations over the PCE through metrics of discrimination, calibration, and reclassification. Although the present study does not validate the full extent of PREVENT on a broader US population by incorporating the new PREVENT elements introduced into the risk estimation rubric, it primarily achieves a comparison of the frameworks of the 2 equations, indicating the comparative superiority of one over the other. The American Heart Association recently proposed a new risk assessment construct, the cardiovascular-kidney-metabolic syndrome, and introduced the accompanying PREVENT equations, which represent an update to the PCEs originally adopted in 2013. 2 ,3 Developed using data from more than 3 million adults from 25 contemporary databases, the PREVENT equations offer an updated estimation of risk, accounting for the changing landscape of risk factors in the population. The PCEs, which were derived from 5 cohorts initially recruited between the 1940s and 1980s, have been criticized for potentially miscalculating risk by not accounting for the current diversity of the US population. 4 Compared with the PCEs, the PREVENT equations omit race, include measures of renal function and statin use, and were developed using more diverse and contemporary cohorts, many of which were derived from electronic health record data. The PREVENT equations also expand the permitted age range in the equations, allow for both 10-year and 30-year risk estimation, and account for new parameters such as the social deprivation index, hemoglobin, and urinary albumin-to-creatinine ratio in the expanded version. The present study 1 is a commendable effort toward the adoption of the base PREVENT equations in current practice, by examining the utility of the tool in the 1999 to 2010 period from the National Health and Nutritional Examination Survey (NHANES). In this contemporary population, the authors report significantly better reclassification of risk by the PREVENT equation compared with the PCE, predominantly as a result of downward reclassification of individuals for whom risk may have been overestimated by PCE. The findings of the present investigation 1 should be interpreted with caution because of certain limitations. First, the full spectrum of outcomes that the PREVENT equations are designed to detect could not be assessed, as the investigators were limited by the variables available in NHANES. Only cardiovascular mortality outcomes were evaluated, with NHANES collapsing International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes to define these outcomes. Consequently, any issues with the definition of outcome events and the exclusion of certain nonfatal cardiovascular events not included in NHANES surveillance preclude a comprehensive assessment of model performance. Ascertainment of nonfatal events would likely correct any overestimation of risk and potentially refine the model, addressing the underfitting reported in the present study. Next, there are a few fundamental considerations regarding the aim of the study to validate the PREVENT score in a nationally representative population. Although NHANES is a large, stratified sample intended to be representative of the US population, the utilization of weighted samples for model comparisons, such as the PCE vs PREVENT in this instance, is often restricted for analytical reasons. The study by Scheuermann et al 1 includes a substantial sample size of 24 582 adults (weighted, 172.9 million) from a US-based population, arguably well-suited for applying the PREVENT and PCE equations and making comparisons based on available clinical variables. However, there were notable deviations in the performance of PREVENT in the present study population compared with those reported in the or -Abstract Truncated-

medicine, general & internal
Alteration in cell division, morphology and motility induced by the toxic principle of lupinosis.

D. Petterson,R. Howlett,T. Robertson,J. Papadimitriou

DOI: https://doi.org/10.1038/ICB.1979.22

1979-04-01

Australian Journal of Experimental Biology and Medical Science

Abstract:
A method for replacing the aortic arch in dogs maintaining normal blood pressures with two pumps and avoiding prolonged use of an oxygenator.

F. Johnson,L. Philipp,J. A. Dowlen,O. N. Filipovich,L. Hughes,C. Hitchcock

Abstract:
Cardiovascular predicted risk: A population-based comparison of the pooled cohorts equation and PREVENT

Rodrigo M Carrillo-Larco

DOI: https://doi.org/10.1016/j.ijcard.2024.132423

2024-11-01

Abstract:Background: While the new cardiovascular risk score (PREVENT) has improvements, its implementation may lead to significant changes in the distribution of atherosclerotic cardiovascular diseases (ASCVD) in the United States. We aimed to quantify and characterize the distribution of the 10-year predicted absolute ASCVD risk using the Pooled Cohorts Equation (PCE) and PREVENT. Methods: We utilized the latest (2017-March 2020) round of the National Health and Nutrition Examination Survey (NHANES). Accounting for the complex survey design of the NHANES, we computed the mean predicted ASCVD risk overall and by sex, race, and education; similarly, we computed the prevalence of cardiovascular risk groups (<5%, 5%-7.4%, 7.5%-19.9%, and ≥ 20%). Results: The study included 3845 observations, representing 109,692,509 people. Using the PREVENT calculator resulted in a reduction of the mean 10-year ASCVD absolute risk by half compared to the PCE: 9.1% vs 4.7%. Under the PCE, the high-risk category accounted for 12.5% of the population, whereas under PREVENT it fell to 0.4%. Among those previously classified as high-risk under the PCE, 3.5% would remain in this category with PREVENT, while 93% would be reclassified as intermediate risk. Conclusions: The adoption of the novel cardiovascular risk score, PREVENT, could lower the average predicted ASCVD risk and reduce the prevalence of high-risk individuals. While this shift might suggest improved cardiovascular health, it could also lead to complacency, potentially undermining ongoing public health efforts aimed at preventing cardiovascular disease.
Predicted Cardiovascular Risk by the PREVENT Equations in US Adults with Stage 1 Hypertension.

Paul Muntner,Byron C. Jaeger,Kathryn Foti,Lama Ghazi,Joshua D. Bundy,Ligong Chen,Monika M. Safford

DOI: https://doi.org/10.1161/hypertensionaha.124.22998

IF: 9.8968

2024-01-01

Hypertension

Abstract:BACKGROUND: The 2017 American College of Cardiology/American Heart Association blood pressure guideline recommends initiation of antihypertensive medication for adults with stage 1 hypertension (systolic blood pressure, 130-139 mm Hg, or diastolic blood pressure, 80-89 mm Hg) and 10-year atherosclerotic cardiovascular disease (ASCVD) risk >= 10% estimated by the pooled cohort equations (PCEs). In 2023, the American Heart Association published the predicting risk of cardiovascular disease events (PREVENT) equations to estimate ASCVD and total cardiovascular disease risk. METHODS: We analyzed US National Health and Nutrition Examination Survey data from 2013 to 2020 for 1703 adults aged 30 to 79 years without self-reported cardiovascular disease with stage 1 hypertension. We estimated 10-year ASCVD risk by the PCEs and 10-year ASCVD and total cardiovascular disease risk by the base PREVENT equations. Analyses were weighted to represent noninstitutionalized US adults with stage 1 hypertension. RESULTS: Mean 10-year ASCVD risk was 5.4% (95% CI, 5.0%-5.9%) and 2.9% (95% CI, 2.7%-3.1%) using the PCEs and PREVENT equations, respectively. The proportion with 10-year ASCVD risk of 10% to <15% and >= 15% was 8.1% and 7.8% estimated by the PCEs, respectively, and 3.0% and 0.3% estimated by the PREVENT equations, respectively. No participants had a 10-year ASCVD risk >= 10% on the PREVENT equations and <10% on the PCEs, while 12.5% had a 10-year ASCVD risk >= 10% on the PCEs and <10% on the PREVENT equations. The mean 10-year total cardiovascular disease risk estimated by the PREVENT equations was lower than the mean 10-year ASCVD risk on the PCEs. CONCLUSIONS: Among US adults with stage 1 hypertension, the 10-year predicted ASCVD risk estimated by the PREVENT equations was approximately half the risk estimated by the PCEs.
Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations

James A. Diao,Ivy Shi,Venkatesh L. Murthy,Thomas A. Buckley,Chirag J. Patel,Emma Pierson,Robert W. Yeh,Dhruv S. Kazi,Rishi K. Wadhera,Arjun K. Manrai

DOI: https://doi.org/10.1001/jama.2024.12537

IF: 11.816

2024-07-29

JAMA

Abstract:Importance Since 2013, the American College of Cardiology (ACC) and American Heart Association (AHA) have recommended the pooled cohort equations (PCEs) for estimating the 10-year risk of atherosclerotic cardiovascular disease (ASCVD). An AHA scientific advisory group recently developed the Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations, which incorporated kidney measures, removed race as an input, and improved calibration in contemporary populations. PREVENT is known to produce ASCVD risk predictions that are lower than those produced by the PCEs, but the potential clinical implications have not been quantified. Objective To estimate the number of US adults who would experience changes in risk categorization, treatment eligibility, or clinical outcomes when applying PREVENT equations to existing ACC and AHA guidelines. Design, Setting, and Participants Nationally representative cross-sectional sample of 7765 US adults aged 30 to 79 years who participated in the National Health and Nutrition Examination Surveys of 2011 to March 2020, which had response rates ranging from 47% to 70%. Main Outcomes and Measures Differences in predicted 10-year ASCVD risk, ACC and AHA risk categorization, eligibility for statin or antihypertensive therapy, and projected occurrences of myocardial infarction or stroke. Results In a nationally representative sample of 7765 US adults aged 30 to 79 years (median age, 53 years; 51.3% women), it was estimated that using PREVENT equations would reclassify approximately half of US adults to lower ACC and AHA risk categories (53.0% [95% CI, 51.2%-54.8%]) and very few US adults to higher risk categories (0.41% [95% CI, 0.25%-0.62%]). The number of US adults receiving or recommended for preventive treatment would decrease by an estimated 14.3 million (95% CI, 12.6 million-15.9 million) for statin therapy and 2.62 million (95% CI, 2.02 million-3.21 million) for antihypertensive therapy. The study estimated that, over 10 years, these decreases in treatment eligibility could result in 107 000 additional occurrences of myocardial infarction or stroke. Eligibility changes would affect twice as many men as women and a greater proportion of Black adults than White adults. Conclusion and Relevance By assigning lower ASCVD risk predictions, application of the PREVENT equations to existing treatment thresholds could reduce eligibility for statin and antihypertensive therapy among 15.8 million US adults.

medicine, general & internal
Cardiovascular Disease Risk Prediction Models in Chinese Population- A Systematic Review and Meta-Analysis

Zhiyong Guo,Jiaying Tang,Hao Han,Yuping Zhang,Qing Yu,Jingfen Jin

DOI: https://doi.org/10.21203/rs.3.rs-1484509/v1

2022-01-01

Abstract:Background: There is an increasing prevalence of CVDs in China which represented the top leading cause of mortality. It is critical to know that precise CVDs risk identification is the fundamental prevention component. This study sought to systematically review the Cardiovascular disease (CVDs) risk prediction models derived and(or) validated in Chinese population to promote CVD primary prevention. Methods: Reports were included if they derived or validated one or more CVDs risk prediction models in the Chinese. Pubmed, Embase, CINAHL, Web of Science, Scopus, China National Knowledge Infrastructure (CNKI), VIP database et al. were searched. Risk of bias was conducted with PROBAST (Prediction model Risk of Bias Assessment Tool). Meta-analysis was performed in R using the package metamisc. Results: From 55183 records, 22 studies were included. Twelve studies derived 18 CVDs risk prediction models, of which seven models were derived based on multicenter cohort including more than two provinces of mainland China, one was model developed based on New Zealand cohort including Chinese. The number of predictors was from 6 to 22. The definitions of predicted outcomes showed considerable heterogeneity. Fourteen articles described 29 validations of 8 models. The Framingham model, the Pooled Cohorts Equations (PCEs) were the most frequently validated foreign tools. Discrimination was acceptable and similar for males and females among models (0.60-0.83). Calibration estimates changed substantially from one population to another. China-PAR showed good calibration [Observed/Expected events ratio=0.99, 95% PI (0.57,1.70)] and female [1.10, 95% PI (0.23,5.16)]. Conclusions: Several models developed or validated in Chinese population. The usefulness of most of the models remains unclear due to incomplete external validation and head-to-head comparison. Future research should focus on externally validating or tailoring these models to local settings. Trail registration: This systematic review was registered at PROSPERO (International Prospective Register of Systematic Reviews, CRD42021277453).
Use of carbohydrate-conjugated nanoparticles for an integrated approach to functional imaging of glycans and understanding of their molecular mechanisms.

N. Nagahori,M. Uchida,M. Kinjo,T. Yamashita

DOI: https://doi.org/10.2174/138920101314151120122746

2012-10-31

Current Pharmaceutical Biotechnology

Abstract:Functional analysis of carbohydrates is needed to understand the initial interface between membranes and the outer world. For this analysis we need individual protocols such as a method to modify the surfaces of nanoparticles with a variety of carbohydrates effectively and exhaustively, to synthesize an oligosaccharide on each particle's surface by chemical or enzymatic sugar elongation reaction, and to analyze the binding properties of carbohydrates. In this article, we describe the basic strategies for scooping up proteins from crude sample mixtures via interaction with carbohydrates. This approach was used to identify proteins that interacted with GM2, a ganglioside that is abundant on the surfaces of human lung cancer cells.
Australia and the South Pacific

D. Arora

DOI: https://doi.org/10.1007/s12231-008-9060-5

2008-11-10

Economic Botany

Abstract:
[Determinants of quitting smoking in Catalonia, Spain].

E. Fernández,J. Carne,A. Schiaffino,J. Borrás,E. Saltó,R. Tresserras,L. Rajmil,J. Villalbí,A. Segura

IF: 2.479

Gaceta Sanitaria

Abstract:OBJECTIVE While trends in the prevalence of smoking and ex-smoking in Catalonia, Spain have been monitored, the characteristics of those smokers who quit have not been investigated. The aim of this investigation was to analyze the prevalence of cessation, or quit ratio, in Catalonia and to study its sociodemographic, life-style, and smoking correlates. SUBJECTS AND METHODS We analyzed data collected in the Catalan Health Interview Survey conducted in 1994. This is a cross-sectional study based on a representative sample of the non-institutionalized population of Catalonia. We included for analysis a total of 5,424 subjects (3,649 males and 1,775 females) who declared to be current smokers (2,335 males and 1,331 females) or past smokers (1,314 males and 444 females). We computed the crude and age-standardized quit ratios (QR) or prevalence of cessation, as well as the odds ratio (OR) of quitting smoking, according to gender and the variables studied. RESULTS The age-standardized QR was 31. 8% for males and 30.9% for females and increased with age. The QR was, both in males and females, greater among married subjects, with higher socioeconomic status, and with healthy life-styles (moderate and heavy leisure physical activity and moderate alcohol consumption). The OR of quitting smoking was higher in heavy smokers (OR = 2.9; 95% CI: 2.2-3.8; smokers of > 30 cigarettes/day vs. 1-10 cigarettes/day) in males, while it was < 1 for females of medium intensity, conforming a shaped curve rather than a linear trend (OR = 1.7; 95% CI: 1.0-2.9, in heavy smokers). CONCLUSIONS This study confirms a positive association in males and females between quitting smoking and increasing age, a higher socioeconomic level, heavy smoking, and healthy life-styles. The identification of these groups should facilitate the planning of successful interventions. Further effort is also necessary to target groups with low cessation rates, such as individuals in disadvantaged social classes and light smokers.
Improving Cardiovascular Disease Primary Prevention Treatment Thresholds in a New England Health Care System

So Mi Jemma Cho,Rachel Rivera,Satoshi Koyama,Min Seo Kim,Shriienidhie Ganesh,Romit Bhattacharya,Kaavya Paruchuri,Patricia Masson,Michael C Honigberg,Norrina B Allen,Whitney Hornsby,Pradeep Natarajan

DOI: https://doi.org/10.1016/j.jacadv.2024.101257

2024-09-06

Abstract:Background: Atherosclerotic cardiovascular disease (ASCVD) risk estimation based on the pooled cohort equation (PCE) overestimates in population-based cohorts. Whether it performs equally across disaggregated demographics in health care populations is less known. Objectives: The purpose of the study was to recalibrate PCE and rederive prevention thresholds in a contemporary health care system and evaluate its performance across sociodemographics. Methods: We retrospectively inspected electronic health records between 2010 to 2012 and 2020 to 2022 within Mass General Brigham health care in New England region. We compared performance of the original vs recalibrated PCE measured by calibration, discrimination, reclassification rate, and net benefit among 160,926 patients aged 40 to 79 years and without prior ASCVD or lipid-lowering medication. Results: Of the 160,926 patients (mean age: 54.6 ± 8.6 years; 61.4% female), 20,373 (12.7%) developed ASCVD over 10 years. The original PCE globally underestimated ASCVD risk (observed vs predicted incidence rate: 0.13 vs 0.05). Recalibration upclassified risk primarily among individuals with low-to-borderline risk by the original PCE and additionally identified 40% of patients who had undergone ASCVD events yet deemed statin-ineligible based on the original PCE. Treatment thresholds yielding the greatest net benefit were ≥24.0% for women (+23.3%) vs ≥26.0% for men (+18.7%), whereas ≥26.0% for White or other race (+24.7%) vs ≥14.0% Black or African American (+12.5%), respectively. Specifically, Hispanic or Latino and non-Hispanic Black patients conferred the greatest sensitivity improvement at ≥12.3% threshold compared to higher ≥23.6% among non-Hispanic Asian or Pacific Islanders. Generally, lower thresholds earlier in life were optimal. Conclusions: Recalibration and personalized treatment thresholds derived within a health system may improve prevention treatment allocation efficiency.
Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis

Johanna A. Damen,Romin Pajouheshnia,Pauline Heus,Karel G. M. Moons,Johannes B. Reitsma,Rob J. P. M. Scholten,Lotty Hooft,Thomas P. A. Debray

DOI: https://doi.org/10.1186/s12916-019-1340-7

IF: 9.3

2019-06-13

BMC Medicine

Abstract:<h3 class="Heading">Background</h3><p class="Para">The Framingham risk models and pooled cohort equations (PCE) are widely used and advocated in guidelines for predicting 10-year risk of developing coronary heart disease (CHD) and cardiovascular disease (CVD) in the general population. Over the past few decades, these models have been extensively validated within different populations, which provided mounting evidence that local tailoring is often necessary to obtain accurate predictions. The objective is to systematically review and summarize the predictive performance of three widely advocated cardiovascular risk prediction models (Framingham Wilson 1998, Framingham ATP III 2002 and PCE 2013) in men and women separately, to assess the generalizability of performance across different subgroups and geographical regions, and to determine sources of heterogeneity in the findings across studies.</p><h3 class="Heading">Methods</h3><p class="Para">A search was performed in October 2017 to identify studies investigating the predictive performance of the aforementioned models. Studies were included if they externally validated one or more of the original models in the general population for the same outcome as the original model. We assessed risk of bias for each validation and extracted data on population characteristics and model performance. Performance estimates (observed versus expected (OE) ratio and c-statistic) were summarized using a random effects models and sources of heterogeneity were explored with meta-regression.</p><h3 class="Heading">Results</h3><p class="Para">The search identified 1585 studies, of which 38 were included, describing a total of 112 external validations. Results indicate that, on average, all models overestimate the 10-year risk of CHD and CVD (pooled OE ratio ranged from 0.58 (95% CI 0.43–0.73; Wilson men) to 0.79 (95% CI 0.60–0.97; ATP III women)). Overestimation was most pronounced for high-risk individuals and European populations. Further, discriminative performance was better in women for all models. There was considerable heterogeneity in the c-statistic between studies, likely due to differences in population characteristics.</p><h3 class="Heading">Conclusions</h3><p class="Para">The Framingham Wilson, ATP III and PCE discriminate comparably well but all overestimate the risk of developing CVD, especially in higher risk populations. Because the extent of miscalibration substantially varied across settings, we highly recommend that researchers further explore reasons for overprediction and that the models be updated for specific populations.</p>

medicine, general & internal
External Validation of the Prognostic Prediction Model for 4-Year Risk of Metabolic Syndrome in Adults: A Retrospective Cohort Study

Hui Zhang,Dandan Chen,Jing Shao,Ping Zou,Nianqi Cui,Leiwen Tang,Dan Wang,Zhihong Ye

DOI: https://doi.org/10.2147/dmso.s316950

2021-01-01

Abstract:Purpose: A prognostic prediction model for metabolic syndrome can help nurses or physicians evaluate the future individual absolute risk of MetS in order to develop personalized care strategies. We aimed to derive and internally validate a prognostic prediction model for 4-year risk of metabolic syndrome in adults. Patients and Methods: This was a retrospective cohort study conducted in a tertiary care setting, and the dataset was obtained from the Healthcare Information and Management Systems of a tertiary hospital. The cohort included Chinese adults attending health examination from 1 January 2011 to 31 December 2014. A total of 6793 participants without metabolic syndrome were included in the cohort and were followed up for 4 years. Available candidate predictors in the dataset were weight, MCV, MCH, AST, ALT, BMI, NGC, TC, serum uric acid, gender, smoking, WBC, LC, Hb, HCT, and age. A logistic regression model was adopted to build the risk equation, and bootstrapping was used when considering internal validation. Calibration, discrimination, and the clinical utility were calculated for the model's performance. Results: Of the 6793 participants, 1750 participants were diagnosed with metabolic syndrome within 4 years. The developed prediction model contained 5 predictors (body mass index, age, total cholesterol, alanine transaminase, and serum uric acid). After internal validation, the C-statistic was 0.783 (95% CI, 0.772-0.795). Additionally, the current model had good calibration. Calibration slope was 0.995 (95% CI, 0.934-1.058), and calibration intercept was -0.008 (95% CI, -0.088-0.073). The Brier score was 0.156. The decision-curve analysis indicated that the prediction model provided greater net benefit than the default strategies of providing treatment or not providing treatment for all patients. Conclusion: A prognostic risk prediction model for determining 4-year risk of metabolic syndrome onset in adults was developed and internally validated. This model was based on routine clinical measurements that quantified individual future risk of metabolic syndrome.
Risk Prediction for Atherosclerotic Cardiovascular Disease With and Without Race Stratification

Arnab K. Ghosh,Sara Venkatraman,Michael G. Nanna,Monika M. Safford,Lisandro D. Colantonio,Todd M. Brown,Laura C. Pinheiro,Eric D. Peterson,Ann Marie Navar,Madeline R. Sterling,Orysya Soroka,Musarrat Nahid,Samprit Banerjee,Parag Goyal

DOI: https://doi.org/10.1001/jamacardio.2023.4520

2024-01-11

JAMA Cardiology

Abstract:Question Is the removal of race stratification from the atherosclerotic cardiovascular disease pooled cohort risk equations (PCEs) associated with a change model performance? Findings In this cohort study of 11 638 participants, removal of race-specific and race-stratified PCEs and the addition of social determinants of health (SDOH) did not change model performance or calibration compared with the original PCE. Meaning Results suggest that removal of race or the addition of SDOH did not improve model performance in any subgroup. Importance Use of race-specific risk prediction in clinical medicine is being questioned. Yet, the most commonly used prediction tool for atherosclerotic cardiovascular disease (ASCVD)—pooled cohort risk equations (PCEs)—uses race stratification. Objective To quantify the incremental value of race-specific PCEs and determine whether adding social determinants of health (SDOH) instead of race improves model performance. Design, Setting, and Participants Included in this analysis were participants from the biracial Reasons for Geographic and Racial Differences in Stroke (REGARDS) prospective cohort study. Participants were aged 45 to 79 years, without ASCVD, and with low-density lipoprotein cholesterol level of 70 to 189 mg/dL or non–high-density lipoprotein cholesterol level of 100 to 219 mg/dL at baseline during the period of 2003 to 2007. Participants were followed up to 10 years for incident ASCVD, including myocardial infarction, coronary heart disease death, and fatal and nonfatal stroke. Study data were analyzed from July 2022 to February 2023. Main outcome/measures Discrimination (C statistic, Net Reclassification Index [NRI]), and calibration (plots, Nam D'Agostino test statistic comparing observed to predicted events) were assessed for the original PCE, then for a set of best-fit, race-stratified equations including the same variables as in the PCE (model C), best-fit equations without race stratification (model D), and best-fit equations without race stratification but including SDOH as covariates (model E). Results This study included 11 638 participants (mean [SD] age, 61.8 [8.3] years; 6764 female [58.1%]) from the REGARDS cohort. Across all strata (Black female, Black male, White female, and White male participants), C statistics did not change substantively compared with model C (Black female, 0.71; 95% CI, 0.68-0.75; Black male, 0.68; 95% CI, 0.64-0.73; White female, 0.77; 95% CI, 0.74-0.81; White male, 0.68; 95% CI, 0.64-0.71), in model D (Black female, 0.71; 95% CI, 0.67-0.75; Black male, 0.68; 95% CI, 0.63-0.72; White female, 0.76; 95% CI, 0.73-0.80; White male, 0.68; 95% CI, 0.65-0.71), or in model E (Black female, 0.72; 95% CI, 0.68-0.76; Black male, 0.68; 95% CI, 0.64-0.72; White female, 0.77; 95% CI, 0.74-0.80; White male, 0.68; 95% CI, 0.65-0.71). Comparing model D with E using the NRI showed a net percentage decline in the correct assignment to higher risk for male but not female individuals. The Nam D'Agostino test was not significant for all race-sex strata in each model series, indicating good calibration in all groups. Conclusions Results of this cohort study suggest that PCE performed well overall but had poorer performance in both BM and WM participants compared with female participants regardless of race in the REGARDS cohort. Removal of race or the addition of SDOH did not improve model performance in any subgroup.

cardiac & cardiovascular systems
Ten-Year Risk Equations for Incident Heart Failure in Established Atherosclerotic Cardiovascular Disease Populations

Luke P Dawson,Melinda J Carrington,Tilahun Haregu,Shane Nanayakkara,Garry Jennings,Anthony Dart,Dion Stub,Michael Inouye,David Kaye

DOI: https://doi.org/10.1161/JAHA.124.034254

2024-06-04

Abstract:Background: Ten-year risk equations for incident heart failure (HF) are available for the general population, but not for patients with established atherosclerotic cardiovascular disease (ASCVD), which is highly prevalent in HF cohorts. This study aimed to develop and validate 10-year risk equations for incident HF in patients with known ASCVD. Methods and results: Ten-year risk equations for incident HF were developed using the United Kingdom Biobank cohort (recruitment 2006-2010) including participants with established ASCVD but free from HF at baseline. Model performance was validated using the Australian Baker Heart and Diabetes Institute Biobank cohort (recruitment 2000-2011) and compared with the performance of general population risk models. Incident HF occurred in 13.7% of the development cohort (n=31 446, median 63 years, 35% women, follow-up 10.7±2.7 years) and in 21.3% of the validation cohort (n=1659, median age 65 years, 25% women, follow-up 9.4±3.7 years). Predictors of HF included in the sex-specific models were age, body mass index, systolic blood pressure (treated or untreated), glucose (treated or untreated), cholesterol, smoking status, QRS duration, kidney disease, myocardial infarction, and atrial fibrillation. ASCVD-HF equations had good discrimination and calibration in development and validation cohorts, with superior performance to general population risk equations. Conclusions: ASCVD-specific 10-year risk equations for HF outperform general population risk models in individuals with established ASCVD. The ASCVD-HF equations can be calculated from readily available clinical data and could facilitate screening and preventative treatment decisions in this high-risk group.
Activation of Wulst in Pied Flycatcher Nestlings during Feeding Behavior Evoked by a Patterned Visual Stimulus

E. Korneeva,A. Tiunova,L. I. Aleksandrov,T. Golubeva

DOI: https://doi.org/10.1007/s11055-017-0415-1

2017-05-05

Neuroscience and Behavioral Physiology

Abstract:
Validation and comparison of cardiovascular risk prediction equations in Chinese patients with Type 2 diabetes

Jingyuan Liang,Qianqian Li,Zhangping Fu,Xiaofei Liu,Peng Shen,Yexiang Sun,Jingyi Zhang,Ping Lu,Hongbo Lin,Xun Tang,Pei Gao

DOI: https://doi.org/10.1093/eurjpc/zwad198

IF: 8.526

2023-06-14

European Journal of Preventive Cardiology

Abstract:Abstract Aims For patients with diabetes, the European guidelines updated the cardiovascular disease (CVD) risk prediction recommendations using diabetes-specific models with age-specific cut-offs, whereas American guidelines still advise models derived from the general population. We aimed to compare the performance of four cardiovascular risk models in diabetes populations. Methods and results Patients with diabetes from the CHERRY study, an electronic health records-based cohort study in China, were identified. Five-year CVD risk was calculated using original and recalibrated diabetes-specific models [Action in Diabetes and Vascular disease: PreterAx and diamicroN-MR Controlled Evaluation (ADVANCE) and the Hong Kong cardiovascular risk model (HK)] and general population-based models [Pooled Cohort Equations (PCE) and Prediction for Atherosclerotic cardiovascular disease Risk in China (China-PAR)]. During a median 5.8-year follow-up, 46 558 patients had 2605 CVD events. C-statistics were 0.711 [95% confidence interval: 0.693–0.729] for ADVANCE and 0.701 (0.683–0.719) for HK in men, and 0.742 (0.725–0.759) and 0.732 (0.718–0.747) in women. C-statistics were worse in two general population-based models. Recalibrated ADVANCE underestimated risk by 1.2% and 16.8% in men and women, whereas PCE underestimated risk by 41.9% and 24.2% in men and women. With the age-specific cut-offs, the overlap of the high-risk patients selected by every model pair ranged from only 22.6% to 51.2%. When utilizing the fixed cut-off at 5%, the recalibrated ADVANCE selected similar high-risk patients in men (7400) as compared to the age-specific cut-offs (7102), whereas age-specific cut-offs exhibited a reduction in the selection of high-risk patients in women (2646 under age-specific cut-offs vs. 3647 under fixed cut-off). Conclusion Diabetes-specific CVD risk prediction models showed better discrimination for patients with diabetes. High-risk patients selected by different models varied significantly. Age-specific cut-offs selected fewer patients at high CVD risk especially in women. Lay summary This large electronic health records-based real-world study indicated that the diabetes-specific cardiovascular risk models had better discriminative abilities than the models derived from the general population in Chinese patients with Type 2 diabetes. Current guidelines-recommended models, i.e. ADVANCE, PCE, and China-PAR, selected significantly different high-risk groups with various observed cardiovascular risks, indicating the potential considerable misclassification of risk stratification in clinical decision-making for preventive interventions.Compared with the fixed cut-off, the influence of the age-specific cut-offs for high risk of cardiovascular disease was different in men and women: age-specific cut-offs selected ∼27% fewer high-risk patients in women but similar in men.

cardiac & cardiovascular systems
Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort

Ailsa J McKay,Laura H Gunn,Kausik K Ray

DOI: https://doi.org/10.1016/j.atherosclerosis.2022.07.011

IF: 5.3

Atherosclerosis

Abstract:Background and aims: The SAFEHEART tool has shown good discrimination in predicting cardiovascular events in a bespoke genotyped cohort with familial hypercholesterolaemia (FH). We assessed whether the tool could aid clinical decision making in an English routine care cohort with FH. Methods: A historical (2000-2017) open cohort of 3643 participants aged 18-79 years and ≥6-months since FH diagnosis was derived from the Clinical Practice Research Datalink. Individual 10-year cardiovascular risks were predicted using the SAFEHEART model, with multiple imputation used to manage missing data. Outcomes were the first occurrence of myocardial infarction, coronary revascularisation, ischaemic stroke, carotid revascularisation, peripheral arterial revascularisation, non-traumatic lower limb amputation, or cardiovascular death. Model performance was assessed using standard measures of calibration and discrimination, and decision curve analysis. Results: 147 outcome events were observed over a median 3.73 (IQR 1.59-6.48) years follow-up. While the model had some discriminatory value (Harrell's c-statistic 0.67 (95% CI 0.61-0.72)), observed outcome risks departed substantially from predicted risks. Calibration slopes for men and women by age decile were 10.09 (95% CI 7.40-12.77) and 2.85 (1.25-4.45), respectively. Recalibration-in-the-large led to closer alignment of observed and predicted risks (recalibration slopes 3.48 (2.55-4.41) and 1.14 (0.50-1.79), respectively). Decision curve analysis suggested the recalibrated model had net benefit at predicted risks of 10-30%. Conclusions: The original SAFEHEART model has limited generalisability to the routinely identifiable English primary care FH population. With recalibration it appears to have moderate utility at 10-30% predicted risk. It may have greater validity in more bespoke genetically defined FH populations.
DISTRIBUTION OF LOCAL ANAESTHETICS: ACCUMULATION IN SOME ENDOCRINE POLYPEPTIDE‐HORMONE PRODUCING CELL SYSTEMS

L. Hammarström,P. Slanina,H. Tjälve,S. Ullberg

DOI: https://doi.org/10.1111/j.1476-5381.1974.tb08604.x

IF: 7.3

1974-11-01

British Journal of Pharmacology

Abstract:1 After the injection of labelled procaine and lidocaine in mice, the location and concentration of radioactivity was demonstrated by autoradiographical methods. 2 An accumulation in some endocrine cells such as the pancreatic islets, the hypophysis, the adrenal medulla and certain cells of the thyroid (probably representing the calcitonin‐producing parafollicular cells) was shown. 3 After the injection of [14C]‐procaine in chicks, an accumulation of radioactivity was observed in the ultimobranchial gland (which produces calcitonin in birds), but not in the thyroid. 4 Radioactivity was also shown to be strongly concentrated in structures containing melanin, such as the pigment of the eye, skin and hair and in some organs involved in the metabolism and excretion of these drugs.

Mutational study of the role of N-terminal amino acid residues in tetrachlorohydroquinone reductive dehalogenase from Sphingomonas sp. UG30.

Validation of American Heart Association PREVENT Cardiovascular Disease Risk Equations

Validating the PREVENT Equations for Cardiovascular Risk Assessment

Alteration in cell division, morphology and motility induced by the toxic principle of lupinosis.

A method for replacing the aortic arch in dogs maintaining normal blood pressures with two pumps and avoiding prolonged use of an oxygenator.

Cardiovascular predicted risk: A population-based comparison of the pooled cohorts equation and PREVENT

Predicted Cardiovascular Risk by the PREVENT Equations in US Adults with Stage 1 Hypertension.

Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations

Cardiovascular Disease Risk Prediction Models in Chinese Population- A Systematic Review and Meta-Analysis

Use of carbohydrate-conjugated nanoparticles for an integrated approach to functional imaging of glycans and understanding of their molecular mechanisms.

Australia and the South Pacific

[Determinants of quitting smoking in Catalonia, Spain].

Improving Cardiovascular Disease Primary Prevention Treatment Thresholds in a New England Health Care System

Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis

External Validation of the Prognostic Prediction Model for 4-Year Risk of Metabolic Syndrome in Adults: A Retrospective Cohort Study

Risk Prediction for Atherosclerotic Cardiovascular Disease With and Without Race Stratification

Ten-Year Risk Equations for Incident Heart Failure in Established Atherosclerotic Cardiovascular Disease Populations

Activation of Wulst in Pied Flycatcher Nestlings during Feeding Behavior Evoked by a Patterned Visual Stimulus

Validation and comparison of cardiovascular risk prediction equations in Chinese patients with Type 2 diabetes

Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort

DISTRIBUTION OF LOCAL ANAESTHETICS: ACCUMULATION IN SOME ENDOCRINE POLYPEPTIDE‐HORMONE PRODUCING CELL SYSTEMS